Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

September 14, 2023
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 14 September 2023, 07:00 CEST alfapump® – strong pivotal POSEIDON data presented at leading international liver congress / on track to file Pre-Market Approval (PMA) application to US FDA in Q4 2023 DSR® – safety of single dose DSR 2.0 demonstrated / Phase 1/2a US MOJAVE study in...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES